Find Clinical Trial
An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in patients with Schnitzler syndrome.
← Back
| Study Phase |
Phase 2 |
| Therapeutic Area |
Immune-Inflammatory Diseases |
| Indication | Schnitzler syndrome |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
GEVOKIZUMAB, |
| Active Substance Code | S078989 |
| Protocol Code | CL2-78989-018 |
| EudraCT Code | 2013-002562-39 |
Documents and links
| Results summary | READ MORE  |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
